The newest generation of antiobesity medications (AOMs)—GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), dual action GLP-1/GIP combinations, triple action injectables, and emerging injectable and oral medications—have changed the landscape for weight management, bringing weight loss success to many for whom weight maintenance had previously not been possible.
Trending
- Iron Deficiency Blocks the Growth of Young Pancreatic Cells
- Teens Using AI Meal Plans Could Be Eating Too Few Calories—Equivalent to Skipping a Meal
- Trends in Digestive Health: Are Microbiome Tests Worth It?
- The Fight for Fair Wages
- A New Consensus on Dietary Therapy for IBD
- TD10
- CPE Monthly: Alpha-Gal Syndrome
- Editor’s Spot: The Elephant in the Room